Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH)

December 7, 2023 updated by: National Institute of Allergy and Infectious Diseases (NIAID)

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11)

This study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergic to more than two other foods, the primary endpoint/outcome in this study will only be assessed in peanut and two other foods for each participant. The primary objective of the study is to compare the ability to consume foods without dose-limiting symptoms during a double-blind placebo-controlled food challenge (DBPCFC), after treatment with either omalizumab or placebo for omalizumab.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Food allergy affects about 15 million people in the United States. This includes 6 million children. The current treatment for food allergy is to avoid eating the foods that may cause an allergic reaction and have medications such as epinephrine (adrenaline) in case of a reaction. However, accidental exposures can be extremely difficult to avoid, particularly if you are allergic to multiple foods. The risks of accidental exposures and life-threatening reactions can place a large burden on patients and their families.

Investigators in this study would like to learn if omalizumab injections alone or in combination with multi-allergen oral immunotherapy (OIT) will help people with multiple food allergies eat foods to which they are allergic. Oral means that you will take the food allergen (peanut and 2 other foods to which you are allergic) by mouth. If you are allergic to more than 3 foods, this study will only provide OIT for peanut and 2 other foods.

There are 3 stages to the study:

In Stage 1, investigators would like to learn:

• If omalizumab stops or decreases allergic reactions to peanut and other common food allergens after taking it for a length of time.

Stage 1 will also have an extra part so that 60 participants will receive omalizumab and everyone (the investigators conducting the research and study participants) will know it. This is why it is called the open label extension. This part of the study will assist investigators in learning if receiving omalizumab for a longer time may work better at decreasing allergic reactions.

In Stage 2, investigators would like to learn:

• How a short course of omalizumab combined with Multi-allergen OIT compares with a longer course of omalizumab in decreasing allergic reactions.

In Stage 3, investigators would like to learn:

• If, after participants stop both treatments, will they be able to eat the peanut and the 2 other foods in the form that is normally eaten.

In all stages, investigators would like to learn:

How safe and effective the treatments are and
How the OIT affects the immune system.

Participation will last up to 56 months (4 years and 8 months).

Study Type

Interventional

Enrollment (Actual)

471

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

United States
- Arkansas
  - Little Rock, Arkansas, United States, 72202
    - Arkansas Children's Hospital Research Institute: Department of Pediatrics, Allergy & Immunology
- California
  - Stanford, California, United States, 94305
    - Stanford School of Medicine: Sean N. Parker Center for Allergy & Asthma Research
- Colorado
  - Denver, Colorado, United States, 80206
    - National Jewish Health: Division of Pediatric Allergy and Clinical Immunology
- Georgia
  - Atlanta, Georgia, United States, 30307
    - Emory University School of Medicine: Children's Healthcare of Atlanta Pediatrics
- Maryland
  - Baltimore, Maryland, United States, 21287
    - Johns Hopkins Children's Center: Department of Allergy & Immunology
- Massachusetts
  - Boston, Massachusetts, United States, 02114
    - Massachusetts General Hospital, Department of Medicine: Allergy & Clinical Immunology Unit
- New York
  - New York, New York, United States, 10029
    - Icahn School of Medicine at Mount Sinai: Department of Pediatrics Allergy & Immunology
- North Carolina
  - Chapel Hill, North Carolina, United States, 27599-7000
    - North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
- Pennsylvania
  - Philadelphia, Pennsylvania, United States, 19104
    - Children's Hospital of Philadelphia: Division of Allergy and Immunology
- Texas
  - Dallas, Texas, United States, 75390
    - University of Texas Southwestern Medical Center: Division of Allergy and Immunology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 55 years (Child, Adult)

Accepts Healthy Volunteers

Description

Inclusion Criteria:

Individuals who meet all of the following criteria are eligible for enrollment as study participants:

Participant and/or parent/legal guardian must be able to understand and provide informed consent and/or assent, as applicable;
Peanut allergic: participant must meet all of the following criteria to minimize the chance that the participant will develop natural tolerance to peanut over the course of the study:
1. Positive skin prick test (SPT) defined as ≥4 mm wheal greater than saline control) to peanut,
2. Positive peanut immunoglobulin E (IgE), ≥6 kUA/L, at Screening or within three months of Screening, determined by ImmunoCap, and
3. Positive double-blind placebo-controlled food challenge (DBPCFC), defined as experiencing dose-limiting symptoms at a single dose of ≤100 mg of peanut protein.
Allergic to at least two of the six other foods (milk, egg, wheat, cashew, hazelnut, walnut): each participant must meet all of the following criteria for at least two of the six other foods to minimize the chance that the participant will develop natural tolerance to at least two of the six other foods over the course of the study:
1. Positive SPT (≥4 mm wheal) to food,
2. Positive food specific IgE (≥6 kUA/L) at Screening or within three months of Screening, determined by ImmunoCap, and
3. Positive DBPCFC, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg of food protein.
With body weight (as measured at Screening) and total serum IgE level (as measured within three months of Screening) suitable for omalizumab dosing;
If female of child-bearing potential, must have a negative urine or serum pregnancy test;
For women of childbearing potential, must agree to,during the treatment period and for 60 days after the last dose of study drug:
- remain abstinent (refrain from heterosexual intercourse), or
- use acceptable contraceptive methods (barrier methods, or
- oral, injected, or implanted hormonal methods of contraception, or
- other forms of hormonal contraception that have comparable efficacy).
Plan to remain in the study area of an OUtMATCH clinical research unit (CRU) during the trial; and
Be willing to be trained on the proper use of an epinephrine autoinjector for the duration of the study.

Exclusion Criteria:

Individuals who meet any of the following criteria are not eligible for enrollment as study participants:

Inability or unwillingness of a participant and/or parent/legal guardian to give written informed consent and/or assent or comply with the study protocol;
Clinically significant laboratory abnormalities at Screening;
Dose-limiting symptoms to the placebo portion of the Screening DBPCFC;
Sensitivity or suspected/known allergy to any ingredients (including excipients) of the
- active or placebo oral food challenge (OFC) material,
- multi-allergen oral immunotherapy (OIT), or
- drugs related to omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin).
  - Note: Guidance for determination of sensitivity to excipients will be detailed in the study's Manual of Procedures (MOP).
Poorly controlled atopic dermatitis (AD) at Screening, per the Principal Investigator's PI's) discretion;
Poorly controlled or severe asthma/wheezing at Screening, defined by at least one of the following criteria:
1. Global Initiative for Asthma (GINA) criteria regarding asthma control latest guidelines,
2. History of two or more systemic corticosteroid courses within six months of Screening or one course of systemic corticosteroids within three months of Screening to treat asthma/wheezing,
3. Prior intubation/mechanical ventilation for asthma/wheezing,
4. One hospitalization or Emergency Department (ED) visit for asthma/wheezing within six months of Screening,
5. Forced expiratory volume in one second (FEV1) <80 percent of predicted or FEV1/forced vital capacity (FVC) <75 percent, with or without controller medications (only for participants who are aged seven years or older and are able to perform spirometry), or
6. Inhaled corticosteroid (ICS) dosing of >500 mcg daily fluticasone (or equivalent ICS based on the National Institutes of Health, National Heart, Lung, and Blood Institute (NHLBI) dosing chart).
History of severe anaphylaxis to participant-specific foods that will be used in this study, defined as neurological compromise or requiring intubation;
Treatment with a burst of oral, intramuscular (IM), or intravenous (IV) steroids of more than two days for an indication other than asthma/wheezing within 30 days of Screening;
Currently receiving oral, intramuscular, or intravenous corticosteroids, tricyclic antidepressants, or beta-blockers (oral or topical);
Past or current history of eosinophilic gastrointestinal (GI) disease within three years of Screening;
Past or current history of cancer, or currently being investigated for possible cancer;
Previous adverse reaction to omalizumab;
Past or current history of any immunotherapy to any of the foods being treated in this study (e.g., OIT, sublingual immunotherapy [SLIT], EPIT) within 6 months of Screening;
Treatment with monoclonal antibody therapy, such as omalizumab (Xolair®), dupilumab (Dupixent®), benralizumab (Fasenra™), mepolizumab (Nucala®), reslizumab (Cinqair®), or other immunomodulatory therapy within six months of Screening;
Currently on "build-up phase" of inhalant allergen immunotherapy (i.e., has not reached maintenance dosing). Note: Individuals tolerating maintenance allergen immunotherapy can be enrolled;
Inability to discontinue antihistamines for the minimum wash-out periods required for SPTs,or OFCs;
Current participation in another therapeutic or interventional clinical trial or participation within 90 days of Screening;
Use of investigational drugs within 24 weeks of Screening;
Pregnant or breastfeeding, or intending to become pregnant during the study or within 60 days after the last dose of omalizumab or placebo for omalizumab;
Has a first-degree relative already enrolled in the study; or
Past or current medical problems (e.g., severe latex allergy), history of other chronic diseases (other than asthma/wheezing, AD, or rhinitis) requiring therapy (e.g., heart disease, diabetes), findings from physical assessment, or abnormalities in clinical laboratory testing that are not listed above, which, in the opinion of the PI, may:
- pose additional risks from participation in the study,
- may interfere with the participant's ability to comply with study requirements, or
- may impact the quality or interpretation of the data obtained from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Sequential Assignment
Masking: Triple

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Stage 1:Omalizumab as Monotherapy Eligible participants are randomized to receive omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table. After 16 weeks of treatment, each participant will complete double-blind placebo-controlled food challenge (DBPCFCs) to each of their three specific foods to a cumulative dose of 6044 mg protein of each food. Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic. The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 Open Label Extension (OLE).All other participants who complete all four DBPCFCs will move Stage 2 of the study.	Drug: Omalizumab Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms. Other Names: Xolair®
Experimental: Stage 1: Omalizumab OLE OLE: Open Label Extension, Long-Term Treatment with Omalizumab. Participants will receive 24 weeks of open label omalizumab in accordance with the omalizumab dosing table defined in the study protocol. Omalizumab is administered by subcutaneous injection either every 2 weeks or every 4 weeks for 24 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table. After 24 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 8044 mg protein of each food. Each participant who completes all four DBPCFCs at the end of the Stage 1 OLE will move on to Stage 3 of the study. Throughout Stage 1 OLE, each participant will be instructed to strictly avoid all foods to which they are allergic.	Drug: Omalizumab Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms. Other Names: Xolair®
Placebo Comparator: Stage 1: Placebo for Omalizumab as Monotherapy Eligible participants are randomized to receive placebo for omalizumab by subcutaneous injection either every 2 weeks or every 4 weeks for 16 to 20 weeks. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table. After 16 weeks of treatment, each participant will complete DBPCFCs to each of their three specific foods to a cumulative dose of 6044 mg protein of each food. Throughout Stage 1, each participant will be instructed to strictly avoid all foods to which they are allergic. The first 60 participants who complete all four DBPCFCs at the end of Stage 1 will participate in the Stage 1 OLE. All other participants who complete all four DBPCFCs will move Stage 2 of the study.	Drug: Placebo for Omalizumab Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms. Other Names: Placebo
Experimental: Stage 2: Omalizumab Participants will receive eight weeks of treatment with open label omalizumab in accordance with the omalizumab dosing table specified in the study protocol, administered by subcutaneous injection. The dose administered and the dosing interval are determined by serum total IgE level and body weight (measured before the start of treatment) per the study drug dosing table. After completion of eight weeks of open label omalizumab, participants will be randomized 1:1 to either: Omalizumab-facilitated oral immunotherapy (OIT): Open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks OR Omalizumab + placebo OIT: Open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks. Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic.	Drug: Omalizumab Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms. Other Names: Xolair®
Experimental: Stage 2: Omalizumab-Facilitated OIT OIT: oral immunotherapy-Omalizumab as Adjunct Therapy to Multi-Allergen Oral Immunotherapy Participants randomized to open label omalizumab + Multi-allergen OIT for eight weeks, followed by placebo for omalizumab + Multi-allergen OIT for 44 weeks. Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic.	Drug: Omalizumab Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms. Other Names: Xolair® Drug: Multi-Allergen Oral Immunotherapy Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours). A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol. Other Names: Multi-Allergen OIT
Experimental: Stage 2: Omalizumab + Placebo OIT OIT: oral immunotherapy Participants randomized to open label omalizumab + placebo for Multi-allergen OIT for eight weeks, followed by omalizumab + placebo for Multi-allergen OIT for 44 weeks. Throughout Stage 2, each participant will be instructed to strictly avoid all foods to which they are allergic.	Drug: Omalizumab Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms. Other Names: Xolair® Drug: Placebo for Multi-Allergen Oral Immunotherapy Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol. Other Names: Placebo for Multi-Allergen OIT
Other: Stage 3: DBPCFC Based Treatment DBPCFC Based Treatment-Long-term Follow-up Treatment Plan for Peanut and Each of the Two Other Participant-Specific Foods. Upon completion of the DBPCFCs at the end of Stage 1 OLE or Stage 2, each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods based on the results of the DBPCFCs. A treatment plan will include instructions for one of the following: Long-term follow-up with dietary consumption of a food; Long-term follow-up with avoidance of a food; or Rescue OIT for a food. The treatment plan for each food may change throughout Stage 3 depending on a participant's response to treatment. Once a participant enters Stage 3, the participant will have a minimum of 12 months follow-up until at least December 2022. Note: Participants will be instructed to strictly avoid a food if they receive rescue OIT for the food during Stage 3.	Other: Double-Blind Placebo-Controlled Food Challenge Based Treatment Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following: Long-term follow-up with dietary consumption of a food; or Long-term follow-up with avoidance of a food; or Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time. Other Names: DBPCFC Based Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants by Stage 1 Treatment Assignment, Omalizumab versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without Dose-Limiting Symptoms During the DBPCFC Conducted at the End of Treatment Stage 1 Time Frame: During the DBPCFC at the end of Stage 1: 16 to 20 weeks after Stage 1 treatment initiation	Number of participants who successfully consume a single dose of ≥600 mg of peanut protein without dose-limiting symptoms during the double-blind placebo-controlled oral food challenge (DBPCFC) conducted in a controlled clinic setting, at the end of Stage 1 treatment, to compare the ability of participants to consume foods without dose-limiting symptoms during a DBPCFC after treatment with either omalizumab or placebo for omalizumab. Dose-limiting symptoms are those that in the view of the principal investigator indicate a true allergic reaction.	During the DBPCFC at the end of Stage 1: 16 to 20 weeks after Stage 1 treatment initiation

Secondary Outcome Measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

Genentech, Inc.

Novartis Pharmaceuticals

Rho Federal Systems Division, Inc.

Investigators

Study Chair: Robert A. Wood, MD, Department of Pediatrics at the Johns Hopkins University School of Medicine
Study Chair: Sharon Chinthrajah, MD, Department of Medicine, Stanford University School of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Sampson HA, Berin MC, Plaut M, Sicherer SH, Jones S, Burks AW, Lindblad R, Leung DYM, Wood RA. The Consortium for Food Allergy Research (CoFAR): The first generation. J Allergy Clin Immunol. 2019 Feb;143(2):486-493. doi: 10.1016/j.jaci.2018.12.989. Epub 2018 Dec 23.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 22, 2019

Primary Completion (Actual)

March 13, 2023

Study Completion (Estimated)

August 1, 2026

Study Registration Dates

First Submitted

March 15, 2019

First Submitted That Met QC Criteria

March 18, 2019

First Posted (Actual)

March 19, 2019

Study Record Updates

Last Update Posted (Actual)

December 8, 2023

Last Update Submitted That Met QC Criteria

December 7, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

DAIT CoFAR-11
CoFAR-11 (Other Identifier: Consortium for Food Allergy Research)
NIAID CRMS ID#: 38625 (Other Identifier: DAIT NIAID)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peanut Allergy

Rima Rachid
University of Minnesota

Recruiting

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

Peanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, Peanut

United States
University of Manitoba
The Hospital for Sick Children; University of British Columbia; McGill University

Enrolling by invitation

Predictors of Persistent Peanut Allergy at Age 5 Years

Allergy to Peanut
Scripps Health
The Scripps Research Institute

Withdrawn

Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy

Food Allergy Peanut

United States
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

Allergy, Peanut

United States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
Imperial College London
University of Sydney; National Institute for Health Research, United Kingdom

Completed

Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study (BOPI-1)

IgE Mediated Peanut Allergy

United Kingdom
King's College London
Charite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UK

Not yet recruiting

TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations (TRANS-FOODS)

Allergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
Imperial College London
University College Cork

Active, not recruiting

Boiled Peanut Immunotherapy for the Treatment of Peanut Allergy (BOPI-2)

Peanut Hypersensitivity | IgE Mediated Peanut Allergy

United Kingdom
University of Rochester
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg (ESCAPE)

Egg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut Allergy

United States
Scott Sicherer
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Immune and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy (CAFETERIA)

Peanut Allergy | Food Allergy

United States
Boston Children's Hospital
Children's Hospital of Philadelphia; Stanford University; Ann & Robert H Lurie...

Completed

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial (PRROTECT)

Peanut Allergy | Food Allergy

United States

Clinical Trials on Omalizumab

Massachusetts General Hospital
Genentech, Inc.

Completed

Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis

Nasal Polyps | Chronic Rhinosinusitis

United States
Medical University of Silesia
Centrum Medyczne Andrzej Bożek

Not yet recruiting

Biologics and Sublingual Immunotherapy (BSIPL)

Asthma, Allergic
Novartis Pharmaceuticals

Completed

Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment (SUNRISE)

CHRONIC SPONTANEOUS URTICARIA

France
Novartis

Completed

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Asthma

Canada
Novartis
Genentech, Inc.; Tanox

Completed

Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.

Asthma

United States, Argentina, Germany
Bernstein Clinical Research Center

Withdrawn

A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Allergy Induced Asthma
The University Clinic of Pulmonary and Allergic...

Unknown

Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions

Allergy | Immunotherapy | Omalizumab | Bee Venom

Slovenia
Stanford University

Completed

Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis (OXAD)

Atopic Dermatitis

United States
Boston Children's Hospital
Stanford University

Completed

Xolair Treatment for Milk Allergic Children

Milk Allergy

United States
IRCCS Policlinico S. Matteo

Completed

Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome (IComaliz)

Interstitial Cystitis | Painful Bladder Syndrome

Italy

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants (OUtMATCH)

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11)

Study Overview

Status

Conditions

Intervention / Treatment

Detailed Description

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Collaborators

Investigators

Publications and helpful links

General Publications

Helpful Links

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Estimated)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Actual)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Peanut Allergy

Clinical Trials on Omalizumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations